Navigation Links
AccuVein Signs Multiple-Country Distribution Agreement in Europe for Vein Illumination Device
Date:10/19/2009

COLD SPRING HARBOR, N.Y., Oct. 19 /PRNewswire/ -- AccuVein LLC today announced a five-year agreement with the Ferrer Group, a leading international pharmaceutical and medical devices distribution company, providing the AccuVein AV300, the world's first hand-held, non-contact vein illumination device, to customers in Greece, Spain and Portugal. The AccuVein AV300 helps healthcare professionals locate veins for blood draw, IV infusion and blood donation by projecting a pattern of light on a patient's skin that reveals vein position.

"Ferrer Group's broad customer base share a common desire - to use advanced medical technology products that add value to reducing costs and improving patient care," said Jose Luis Lirio, Ferrer Group. "We're pleased to bring the world's only portable vein illumination device into our distribution."

"This agreement significantly expands the AV300's global availability into these important markets," said Stephen P. Conlon, President of AccuVein. "Healthcare practitioners in Greece, Spain and Portugal now have access to the device to reduce time and effort in accessing veins."

For more information on the AccuVein AV300, please visit www.AccuVein.com.

About AccuVein

AccuVein applies advanced technologies to important healthcare challenges. Their innovative AV300 allows practitioners to see a map on the patient's skin of the position of peripheral veins, helping caregivers locate these veins while they perform the most common invasive medical procedure - venipuncture. Built using AccuVein's expertise in medical device miniaturization and user-intuitive design, the AV300 is the world's first portable, non-contact vein illumination solution. With more than a dozen patents filed worldwide, AccuVein demonstrates an ongoing commitment to invest in improving patient care and patient satisfaction.

For more information on the AccuVein AV300, please visit www.AccuVein.com.

About Ferrer Group

Ferrer Group is comprised of over 50 companies operating in Pharmacy, Food and Fine Chemicals, three key areas to assist in improving health and quality of life of people. Grupo Ferrer Internacional serves customers in France, Italy, Belgium, Portugal, and Greece, as well as in Spain, Germany, the Middle East, South America, Africa, and the Far East. Grupo Ferrer Internacional, S.A. was founded in 1959 and is based in Barcelona, Spain.

SOURCE AccuVein LLC


'/>"/>
SOURCE AccuVein LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
2. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
3. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
4. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
5. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
6. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
9. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
10. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
11. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):